AKT1 and cancer: Li et al. [36] found that continuous activation of the PI3K/Akt signaling pathway could enhance cellular resistance to gefitinib and erlotinib, and that a blocker of PI3K/Akt signaling increased the sensitivity of cancer cells to both of those agents by inducing apoptosis in both in vitro and in vivo models.